By comparison, the immunoreactivity in MTSCC-K was as follows: AMACR, 93%; CK7, 81%; EMA, 95%; RCC Ma, 7%; CD10, 15%; HMWK, 15%; and c-kit, 5%. This evidence concerns the gene KIT and renal cell carcinoma.